Fabry’s disease is a sex-linked recessive storage disorder leading to cerebrovascular symptoms in many cases. Whether the primary origin of cerebrovascular symptoms in these patients is due to autochthonous thrombosis of small vessels or embolic infarction from large vessels is under debate. Microembolic signals (MES) indicative of an active embolic source can be recorded by transcranial Doppler sonography. We report four patients (34, 44, 62 and 66 years old) with Fabry’s disease from one kindred in whom we carried out microembolus detection recordings to disclose active embolic sources. Three of the patients had had transient focal neurological deficits. Two patients had angina pectoris and one had exercise dyspnea, but no patient had clear evidence of disease of the large coronary vessels or brain-supplying arteries. No MES were found in 1-hour recordings in any patients, supporting the hypothesis that early cerebrovascular symptoms arise from small vessel occlusion and not from embolic sources as an indicator of disease of large brain-supplying arteries or cardiac embolism.

1.
Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry’s disease: Ceramide trihexosidase deficiency. N Engl J Med 1967;276:1163–1167.
2.
Desnick RJ, Astrin KH, Bishop DF: Fabry’s disease: Molecular genetics of the inherited nephropathy. Adv Nephrol Necker Hosp 1989;18:113–127.
3.
Mitsias P, Levine SR: Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8–17.
4.
Crutchfield K, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, Schiffmann R: Quantitative analysis of cerebral vasculopathy in patients with Fabry’s disease. Neurology 1998;50:1746–1749.
5.
Scott LJ, Griffin JW, Luciano C, Barton NW, Banerjee T, Crawford T, McArthur JC, Tournay A, Schiffmann R: Quantitative analysis of epidermal innervation in Fabry’s disease. Neurology 1999;52:1249–1254.
6.
Kocen RS, Thomas PK: Peripheral nerve involvement in Fabry’s disease. Arch Neurol 1970;22:81–88.
7.
Maisey DN, Cosh JA: Basilar artery aneurysm and Anderson-Fabry’s disease. J Neurol Neurosurg Psychiatry 1980;43:85–87.
8.
Dilorenzo PA, Kleinfeld J, Tellman W, Nay L: Angiokeratoma corporis diffusum. (Fabry’s disease). Acta Derm Venereol 1969;49:319–325.
9.
Spencer MP, Thomas GI, Nicholls SC, Sauvage LR: Detection of middle cerebral artery emboli during carotid endarterectomy using transcranial Doppler ultrasonography. Stroke 1990;21:415–423.
10.
Sliwka U, Lingnau A, Stohlmann WD, Schmidt P, Mull M, Diehl RR, Noth J: Prevalence and time course of microembolic signals in patients with acute stroke. A prospective study. Stroke 1997;28:358–363.
11.
Droste DW, Ritter M, Kemeny V, Schulte-Altedorneburg G, Ringelstein EB: Microembolus detections at follow-up in 19 patients with acute stroke: Correlation with stroke etiology and antithrombotic treatment. Cerebrovasc Dis 2000;10:272–277.
12.
Sitzer M, Söhngen D, Siebler M, Specker C, Rademacher J, Janda I, Aulich A, Steinmetz H: Cerebral microembolism in patients with Sneddon’s syndrome. Arch Neurol 1995;52:271–275.
13.
Rademacher J, Söhngen D, Specker C, Janda I, Sitzer M: Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus? Acta Neurol Scand 1999;99:356–361.
14.
Sakuraba H, Igarashi T, Shibata T, Suzuki Y: Effect of vitamin E and ticlopidine on platelet aggregation in Fabry’s disease. Clin Genet 1987;31:349–354.
15.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001;345:55–57.
16.
Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO: Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry’s disease. Proc Natl Acad Sci USA 2000;97:365–370.
17.
Brady RO, Schiffmann R: Clinical features of and recent advances in therapy for Fabry’s disease. JAMA 2000;284:2771–2775.
18.
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O’Callaghan M, Desnick RJ: A phase 1/2 clinical trial of enzyme replacement in Fabry’s disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711–722.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.